| Dr Brian Bishop Moon, MD | |
|
3599 University Blvd. S., Bldg. 300, Jacksonville, FL 32216 | |
| (904) 399-5550 | |
| (904) 346-4334 |
| Full Name | Dr Brian Bishop Moon |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | 3599 University Blvd. S., Jacksonville, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003018342 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | ME115592 (Florida) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | ME115592 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center - Jacksonville | Jacksonville, FL | Hospital |
| Orange Park Medical Center | Orange park, FL | Hospital |
| Memorial Hospital Jacksonville | Jacksonville, FL | Hospital |
| Baptist Medical Center Beaches | Jacksonville beach, FL | Hospital |
| Wellstar West Georgia Medical Center | Lagrange, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
News Archive
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review of studies about parents' diet and the immunity of animal offspring has found a close relationship exists, with implications for wildlife conservation and livestock rearing as well as human health.
A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.
› Verified 1 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review of studies about parents' diet and the immunity of animal offspring has found a close relationship exists, with implications for wildlife conservation and livestock rearing as well as human health.
A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.
› Verified 1 days ago
| Entity Name | Georgia Radiology Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831461771 PECOS PAC ID: 5698930774 Enrollment ID: O20170111000386 |
News Archive
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review of studies about parents' diet and the immunity of animal offspring has found a close relationship exists, with implications for wildlife conservation and livestock rearing as well as human health.
A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.
› Verified 1 days ago
| Entity Name | Northside Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960657 PECOS PAC ID: 4486555398 Enrollment ID: O20200914002464 |
News Archive
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review of studies about parents' diet and the immunity of animal offspring has found a close relationship exists, with implications for wildlife conservation and livestock rearing as well as human health.
A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Bishop Moon, MD 3599 University Blvd. S., Bldg. 300, Jacksonville, FL 32216 Ph: (804) 828-9783 | Dr Brian Bishop Moon, MD 3599 University Blvd. S., Bldg. 300, Jacksonville, FL 32216 Ph: (904) 399-5550 |
News Archive
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review of studies about parents' diet and the immunity of animal offspring has found a close relationship exists, with implications for wildlife conservation and livestock rearing as well as human health.
A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.
› Verified 1 days ago
Dr. Rishi Norman Razdan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2416 Dunn Ave, Jacksonville, FL 32218 Phone: 904-353-3664 Fax: 904-353-3858 | |
Dr. Travis Howell Edelstein, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 655 W 8th St, 2nd Floor Clinical Center University Of Florida Jackson, Jacksonville, FL 32209 Phone: 954-775-4645 | |
Leo Czervionke, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Nina L Kazerooni, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 7908 Monterey Bay Dr, Jacksonville, FL 32256 Phone: 904-507-9318 | |
Dr. Clyde Whitley Vick Iii, MD Radiology Medicare: Medicare Enrolled Practice Location: 1833 Boulevard, Jacksonville, FL 32206 Phone: 904-232-2751 Fax: 904-232-2482 | |
Beau Toskich, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 |